Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 2/20 | 0.68 |
| ▸ | DRD4 | P21917 | 2/20 | 0.68 |
| ▸ | DRD5 | P21918 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7332018 | 0.86 | HRH1 (0.67) | DRD1DRD4DRD5KDM4EL3MBTL1 | |
| SCHEMBL1600507 | 0.85 | CNR1 (0.61) | DRD1DRD4DRD5POLBKDM4E | |
| SCHEMBL6690875 | 0.85 | DRD1 (0.65) | DRD1DRD4DRD5POLBKDM4E | |
| SCHEMBL240294 | 0.83 | DRD1 (0.71) | DRD1DRD4DRD5POLBKDM4E | |
| SCHEMBL7123326 | 0.83 | DRD1 (0.71) | DRD1DRD4DRD5POLBKDM4E | |
| Hydrochloric Acid SCHEMBL14966707 | 0.82 | DRD1 (0.69) | DRD1DRD4DRD5POLBKDM4E | |
| SCHEMBL6997049 | 0.82 | DRD1 (0.72) | DRD1DRD4DRD5POLBKDM4E | |
| SCHEMBL6042440 | 0.81 | POLB (0.68) | DRD1DRD4DRD5POLBKDM4E | |
| SCHEMBL8475269 | 0.81 | L3MBTL1 (0.74) | DRD1DRD4DRD5POLBKDM4E | |
| SCHEMBL110986 | 0.81 | DRD1 (0.71) | DRD1DRD4DRD5POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004096811-A1 | PDE9 INHIBITORS FOR TREATING TYPE 2 DIABETES, METABOKIC SYNDROME, AND CARDIOVASCULAR DISEASE | PFIZER PRODUCTS INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PFIZER INC. | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PDE9A, PDE2A, PDE12 | DRD1 2310/4885DRD4 3777/4885DRD5 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.